CD5 and lymphoproliferative syndrome: The plasma concentration of B-lymphocyte stimulator was high in the patient and fell dramatically after chemotherapy, indicating that chronic stimulation of B-cell clones, particularly CD5+, by B-lymphocyte stimulator could favor the development of both autoimmune diseases and a broad range of lymphoproliferative disorders (such as Castleman disease).[13]